Opdivo and Haemolysis - a phase IV clinical study of FDA data

Summary:

Haemolysis is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Yervoy, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Haemolysis when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Haemolysis?

Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid) is found to be associated with 613 drugs and 837 conditions by eHealthMe. Check the latest studies of Haemolysis.

On Jul, 13, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 18 people (0.03%) have Haemolysis.

Among these 18 people:

How long have people been on Opdivo when they have Haemolysis? *

What is the gender of people who have Haemolysis when taking Opdivo? *

female: 76.47 %
male: 23.53 %

What is the age of people who have Haemolysis when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Haemolysis? *

Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 22.22%
Bleeding Disorders: 3 people, 16.67%
Viral Infection: 3 people, 16.67%
Tremor (trembling or shaking movements in one or more parts of your body): 3 people, 16.67%
Splenomegaly (enlargement of spleen): 3 people, 16.67%
Renal Impairment (severely reduced kidney function): 3 people, 16.67%
Post Procedural Haemorrhage (post procedural bleeding): 3 people, 16.67%
Autoimmune Pancytopenia (abnormal deficiency in all blood cells by immune system deficiency): 3 people, 16.67%
Pneumonia: 3 people, 16.67%
Fever: 3 people, 16.67%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 6 people, 33.33%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 22.22%
Type 2 Diabetes: 1 person, 5.56%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 1 person, 5.56%
Renal Cell Carcinoma (a kidney cancer): 1 person, 5.56%
Pain: 1 person, 5.56%
Oesophageal Carcinoma (cancer tumour of oesophagus): 1 person, 5.56%
Nausea (feeling of having an urge to vomit): 1 person, 5.56%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 5.56%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Haemolysis?

- Check whether Haemolysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Haemolysis treatments and more:

Haemolysis (9,155 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haemolysis:

Haemolysis (613 drugs)

Browse all the conditions that are associated with Haemolysis:

Haemolysis (837 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.